Niaid-VRC-research, development, and production to support clinical testing of vaccines against seasonal or pandemic influenza viruses
Active Awarded Last action
- Contract number
- 75N91022F00014
- Awardee
-
Leidos Biomedical Research Inc. UEI HV8BH9BPG8Y9 Part of Leidos Holdings, Inc.
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,269,688
Award facts
- Contract value 35% obligated
-
- $11,269,688.00 Current, with exercised options
- $31,997,746.00 Potential, with all options
- Completion date 69% complete
- Current and potential, with all options
- Funding agency
- National Institute of Allergy and Infectious Diseases National Institutes of Health, Department of Health and Human Services
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Frederick, MD 21702, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Exercise an Option | $4,729,156 | |
| Original award | $6,540,532 |
About this award
The National Institutes of Health National Institute of Allergy and Infectious Diseases awarded a $31,997,746.00 cost plus fixed fee contract to Leidos Biomedical Research Inc. to support clinical testing of vaccines against seasonal or pandemic influenza viruses from September 12, 2022 through August 24, 2028. Leidos Biomedical Research Inc. will serve as the prime contractor and will utilize two subcontracts with the University of Pittsburgh, which will be responsible for housing and caring for cynomolgus macaques and executing influenza challenges in an ABSL-3 environment to evaluate protective efficacy of monoclonal antibody prophylaxis through passive immunization studies.
Quick answers
Who was awarded contract 75N91022F00014?
75N91022F00014 was awarded to Leidos Biomedical Research Inc. by National Cancer Institute (National Institutes of Health) on September 12, 2022.
How much is contract 75N91022F00014 worth?
The government has obligated $11,269,688 on 75N91022F00014. Its potential value, with all options, is $31,997,746.
Which agency awarded contract 75N91022F00014?
National Cancer Institute (National Institutes of Health) awarded 75N91022F00014, with funding from National Institute of Allergy and Infectious Diseases (National Institutes of Health).
Is contract 75N91022F00014 an order under another contract?
Yes. 75N91022F00014 is a delivery order under 75N91019D00024, an indefinite delivery contract.
Was contract 75N91022F00014 competed?
The extent of competition for 75N91022F00014 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award